Nycomed and Micromet entered into research collaboration agreement to develop Micromet’s anti-GM-CSF antibodies, including MT203 for treating inflammatory and autoimmune diseases. The deal would worth up to €125 M (US$168.7 M) to Micromet if specific milestones and sales targets are met.